Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Intimation of Earnings Presentation for Quarter 4 - Financial Year 2021-2022 [Q4-FY22/FY22] Further to our intimation dated May 30, 2022 regarding approval of Audited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and financial year ended March 31, 2022, we hereby enclose a copy of Earnings Presentation for Quarter 4 - Financial Year 2021-2022. The said Earnings Presentation will thereafter be uploaded on Company's website at www.fermentabiotech.com Kindly take the same on record.
31-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Publication Of Audited Financial Results For The Quarter And Financial Year Ended March 31, 2022

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide our letter dated May 30, 2022, regarding declaration of Audited Financial Results for the quarter and financial year ended March 31, 2022, we are enclosing herewith photocopy of the newspaper publications published in Business Standard, Mumbai (English version) on page no. 13 and in Sakal, Mumbai (Marathi version) on page no. 11 dated May 31, 2022 for your reference and record.
31-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report for the year ended March 31, 2022 under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to the provisions of Regulation 24A of the Listing Regulations read with SEBI circular CIR/CFD/CMD1/27/2019 dated February 8, 2019, we are enclosing the annual secretarial compliance report for the year ended March 31, 2022, issued by Pradeep Purwar & Associates, Company Secretaries.
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Outcome Of Board Meeting - Regulation 4 And 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

 We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia, approved / recommended the following: 1. Annual General Meeting (AGM) Date, 2. Dividend and Record Date, 3. Dividend Payment Date, 4. Appointment of new Statutory Auditors, 5. Appointment of Mr. Pramod Kasat (DIN: 00819790) as an Additional Director w.e.f. May 30, 2022 to hold office till the conclusion of ensuing 70th AGM., 6. Appointment of Mr. Pramod Kasat (DIN: 00819790) as an Independent Director for a period of 5 years w.e.f. August 12, 2022, subject to members' approval at the 70th AGM, 7. Re-appointment of Mr. Satish Varma (DIN: 00003255) as an Executive Director of the Company for a period of 3 years w.e.f. September 27, 2022, subject to members' approval at the 70th AGM, 8. Re-appointment of Ms. Anupama Datla Desai (DIN: 00217027) as an Executive Director of Company for a period of 3 years w.e.f. September 27, 2022, subject to members' approval at 70th AGM
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Earnings conference call under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to discuss the financial performance of the Company for the quarter and financial year ended March 31, 2022 ['Q4-FY22/FY22'] Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the earnings conference call is scheduled to be held on Wednesday, June 1, 2022, to discuss the financial performance of the Company for the quarter and financial year ended March 31, 2022. The invite for the said earnings conference call is enclosed herewith. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Board recommends Final Dividend

 Fermenta Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5 each for the financial year ended March 31, 2022 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately).
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Outcome Of Board Meeting And Financial Results - Regulation 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

 We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia: 1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 as per Regulation 33 of the Listing Regulations. The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, Deloitte Haskins & Sells, LLP, Chartered Accountants, dated May 30, 2022 are enclosed herewith. 2. Recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5 each for the financial year ended March 31, 2022 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately). The Board meeting commenced at 12.30 p.m. and concluded at 03.20 p.m.
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Board Meeting Outcome for Outcome Of Board Meeting And Financial Results - Regulation 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

 We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia: 1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 as per Regulation 33 of the Listing Regulations. The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, Deloitte Haskins & Sells, LLP, Chartered Accountants, dated May 30, 2022 are enclosed herewith. 2. Recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5 each for the financial year ended March 31, 2022 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately). The Board meeting commenced at 12.30 p.m. and concluded at 03.20 p.m.
30-05-2022
Bigul

Annual report for Fermenta Biotech Ltd. for FY-2022
30-05-2022
Bigul

Fermenta Biotech Ltd - 506414 - Board to consider Final Dividend

 Fermenta Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be heldon May 30, 2022, inter alia:1. To consider and approve the audited financial results of the Company (standalone and consolidated) for the quarter and financial year ended March 31, 2022; and2. To consider and recommend final equity dividend, if any, for the financial year 2021-22.In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company''s Code of Conduct to Regulate, Monitor and Report Trading by Insiders and in terms of BSE Circular dated April 02, 2019, the 'Trading Window" (period for trading in Company's securities) has been closed with effect from April 01, 2022 and shall continue to remain closed till 48 hours after declaration of audited financial results for the quarter and financial year ended March 31, 2022. During the closure of Trading Window, all Directors, Promoters, Insiders, Designated Persons including Auditors shall not, directly or indirectly trade or deal or enter into any transaction involving sale or purchase of the Company's Equity Shares, either in their own name or in the name of their immediate relatives.Terms not defined in this notice shall have the same meaning as defined in the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct to Regulate, Monitor and Report Trading by Insiders.
23-05-2022
Next Page
Close

Let's Open Free Demat Account